Withdraw Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial

Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029572

Enrollment

Unknown

Registered

2020-02-05

Start date

2020-02-05

Completion date

Unknown

Last updated

2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

control group:Conventional treatment

experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial version 4). Only patients with severe and critical 2019-ncov were included in this study. 1. Patients with severe 2019-ncov according to the clinical stage met any of the following criteria: (1) Respiratory distress, RR >= 30 times/min; (2) In resting state, oxygen saturation is less than 93%; (3) Partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) <= 300mmHg (1mmHg= 0.133kpa); 2. According to the clinical stage of critical 2019-ncov, one of the following conditions is met: (1) Respiratory failure occurs and mechanical ventilation is required; (2) Shock; (3) Combined with other organ failure, intensive care unit is required. 3. Other inclusion criteria: good compliance, willingness to cooperate with the study, and informed consent signed by the patient.

Exclusion criteria

Exclusion criteria: 1. Have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy; 2. Other circumstances that the researcher considers inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
PSI;	—

Secondary

Measure	Time frame
CT;X-ray;Arterial blood gas analysis;Assisted breathing use time;mortality;Disease evolution;hospitalization day;Safety outcome index;	—

Countries

China

Contacts

Public ContactPei Bei

Xiangyang First People's Hospital

xyxzyxzh@163.com+86 18995678520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026